You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.
This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
A study to assess the real-life management and use of healthcare resources during the initiation of venetoclax in participants with chronic lymphocytic leukemia (CLL) with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.
This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
The SOLACE study will help us generate and advance scientific knowledge of real-life management of hidradenitis suppurativa and the condition’s burden on people with moderate to severe HS.
The Cadence study will help us assess the impact of treatment with DUODOPA on Canadian patients with advanced Parkinson’s disease (PD).
Duodopa is the commercial name for a levodopa/carbidopa combination that comes in gel form. It is delivered inside the upper intestine via a small tube inserted directly into the first part of the small bowel, or duodenum. This unique delivery system – called intraduodenal infusion – uses a programmable pump to let the physician and patient individually tune the delivery of active ingredients, suspended as a stable gel, from a cassette worn outside the body.
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Canada.
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).
To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
To give you the best possible user experience, this site uses cookies and by continuing to use this site, you agree that this site saves them on your devices for analytics purposes and to remember your preferences. For more information, please read our terms of use and our Privacy policy.
